Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Molecular testing in cost-effective targeted therapies

Ghassan Abou-Alfa • 2 Jun 2021
ASCO 2021

Ghassan K. Abou-Alfa, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the role of molecular testing in the development of cost-effective targeted therapies. Prof. Abou-Alfa highlights the importance of mass next-generation sequencing (NGS) and discusses novel approaches which aim to circumvent the operational and financial limitations currently associated with it. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

More from Ghassan Abou-Alfa

2:19
Should HCC be treated with locoregional or systemic therapies?
Ghassan Abou-Alfa • 22 Jun 2023
2:32
The role of systemic treatment in early-stage hepatocellular carcinoma
Ghassan Abou-Alfa • 22 Jun 2023
1:53
SCG101: a novel T-cell therapy in advanced hepatitis B-related HCC
Ghassan Abou-Alfa • 22 Jun 2023
3:52
What role does TIGIT inhibition have in treating hepatocellular carcinoma?
Ghassan Abou-Alfa • 22 Jun 2023
The content of VJOncology is intended for healthcare professionals